Program
Oncolytic HSV-1 Expressing IL-12 and IL-15/IL-15-receptor Alpha VG2025
Also written as “VG2025” and “Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection”.
Its studies are mostly in Cholangiocarcinoma · Neuroendocrine Tumors, led by 3 companies.
Drug pageOncolytic HSV-1 Expressing IL-12 and IL-15/IL-15-receptor Alpha VG2025: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Virogin Biotechits history only | 11 open or running | phase 1since Jul 15, 2022 | Jul 15, 2022 | none ahead |
| Virogin Biotech Canadaits history only | 11 open or running | phase 1since Feb 9, 2022 | Feb 9, 2022 | none ahead |
| Virogin Biotechits history only | 11 open or running | phase 2since Apr 1, 2026 | Apr 1, 2026 | Jan 18, 2028phase 2 · NCT07522476 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 9, 2022First study: phase 1 study in Neuroendocrine TumorsNew to Virogin Biotech CanadaVirogin Biotech Canada · NCT05266612 · 12 planned · United States
- Jul 15, 2022Shanghai Virogin Biotech’s first study: phase 1 study in Advanced Malignant Solid TumorNew to Shanghai Virogin BiotechShanghai Virogin Biotech · NCT05477849 · 30 planned · China
- Apr 1, 2026Virogin Biotech’s first study: phase 2 study in CholangiocarcinomaNew to Virogin BiotechVirogin Biotech · NCT07522476 · 30 planned · China
Ahead
- Jan 18, 2028Primary completion: phase 2 study in CholangiocarcinomaVirogin Biotech · NCT07522476
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07522476Cholangiocarcinoma · China | 2 | Recruiting | Virogin Biotech | Jan 18, 2028 | 30 |
| NCT05477849Advanced Malignant Solid Tumor · China | 1 | Recruiting | Shanghai Virogin Biotech | Oct 31, 2025 | 30 |
| NCT05266612Neuroendocrine Tumors · United States | 1 | Recruiting | Virogin Biotech Canada | Dec 31, 2024 | 12 |
How it is read
Names in the registry
- “VG2025”, 2 entries
- “Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection”, 1 entry
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 1 study
- Neuroendocrine Tumors, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.